Genentech Alecensa: 'Unprecedented' Phase III Results in Early-Stage Lung Cancer

 

• ALINA data demonstrate Alecensa reduces disease recurrence in the early setting for people with ALK-positive non-small cell lung cancer (NSCLC), building on its long-established benefit in the advanced setting
• About half of people with NSCLC experience disease recurrence following surgery, despite adjuvant chemotherapy, therefore new treatments are urgently needed to provide the best chance for cure
• These data will be submitted to health authorities globally and presented at an upcoming medical meeting

https://www.biospace.com/article/releases/genentech-s-alecensa-delivers-unprecedented-phase-iii-results-for-people-with-alk-positive-early-stage-lung-cancer/